Jessica Hope Roark

Array ( [id] => 10791578 [patent_doc_number] => 20160137733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'THERAPEUTIC CD47 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/940751 [patent_app_country] => US [patent_app_date] => 2015-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13896 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10791577 [patent_doc_number] => 20160137734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'THERAPEUTIC CD47 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/940755 [patent_app_country] => US [patent_app_date] => 2015-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14000 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058647 [patent_doc_number] => 20170334991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'ANTI-CLDN CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/524675 [patent_app_country] => US [patent_app_date] => 2015-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 45377 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11032967 [patent_doc_number] => 20160229923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-11 [patent_title] => 'ANTI-CEA ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/928819 [patent_app_country] => US [patent_app_date] => 2015-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 33424 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14928819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10685801 [patent_doc_number] => 20160031946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'MULTI-EPITOPIC VACCINE' [patent_app_type] => utility [patent_app_number] => 14/883668 [patent_app_country] => US [patent_app_date] => 2015-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 14114 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14883668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10761977 [patent_doc_number] => 20160108130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'RSPO3 Binding Agents and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/870145 [patent_app_country] => US [patent_app_date] => 2015-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 63886 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14870145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11343518 [patent_doc_number] => 09527914 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-27 [patent_title] => 'Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies' [patent_app_type] => utility [patent_app_number] => 14/857344 [patent_app_country] => US [patent_app_date] => 2015-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 139 [patent_figures_cnt] => 190 [patent_no_of_words] => 76987 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 217 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14857344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971193 [patent_doc_number] => 20170275347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'METHODS FOR IDENTIFYING PATIENTS RESPONSIVE TO ANTI-PD-L1 ANTIBODY THERAPY' [patent_app_type] => utility [patent_app_number] => 15/508514 [patent_app_country] => US [patent_app_date] => 2015-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 10092 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15508514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13154065 [patent_doc_number] => 10093746 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => Glypican-3 antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 15/508317 [patent_app_country] => US [patent_app_date] => 2015-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 23878 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15508317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11054473 [patent_doc_number] => 20160251435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/841619 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 36290 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10799199 [patent_doc_number] => 20160145354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/835439 [patent_app_country] => US [patent_app_date] => 2015-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 129 [patent_figures_cnt] => 129 [patent_no_of_words] => 76509 [patent_no_of_claims] => 68 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14835439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10699405 [patent_doc_number] => 20160045551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 14/835264 [patent_app_country] => US [patent_app_date] => 2015-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 27801 [patent_no_of_claims] => 84 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14835264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700581 [patent_doc_number] => 20160046727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF' [patent_app_type] => utility [patent_app_number] => 14/830336 [patent_app_country] => US [patent_app_date] => 2015-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 64 [patent_no_of_words] => 40399 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14830336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314241 [patent_doc_number] => 20180208657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => RECOMBINANT ANTIBODY MOLECULE AND ITS USE FOR TARGET CELL RESTRICTED T CELL ACTIVATION [patent_app_type] => utility [patent_app_number] => 15/503703 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27833 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13154011 [patent_doc_number] => 10093717 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => Chimeric antigen receptor containing a toll-like receptor intracellular domain [patent_app_type] => utility [patent_app_number] => 15/112619 [patent_app_country] => US [patent_app_date] => 2015-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 5190 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15112619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11480497 [patent_doc_number] => 09587028 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-07 [patent_title] => 'Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use' [patent_app_type] => utility [patent_app_number] => 14/820882 [patent_app_country] => US [patent_app_date] => 2015-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 90 [patent_no_of_words] => 33630 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 463 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14820882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448602 [patent_doc_number] => 09982053 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Immunological reagents [patent_app_type] => utility [patent_app_number] => 15/329760 [patent_app_country] => US [patent_app_date] => 2015-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14318 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1001 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15329760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11908269 [patent_doc_number] => 09777073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-03 [patent_title] => 'Construction and application of bispecific antibody EpCAM×CD3' [patent_app_type] => utility [patent_app_number] => 14/803298 [patent_app_country] => US [patent_app_date] => 2015-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 15 [patent_no_of_words] => 9360 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14803298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10799182 [patent_doc_number] => 20160145339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'Construction and application of bispecific antibody HER2xCD3' [patent_app_type] => utility [patent_app_number] => 14/803278 [patent_app_country] => US [patent_app_date] => 2015-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10124 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14803278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15227653 [patent_doc_number] => 10501537 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => Methods for treating cancer [patent_app_type] => utility [patent_app_number] => 15/325036 [patent_app_country] => US [patent_app_date] => 2015-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 7243 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15325036 [rel_patent_id] =>[rel_patent_doc_number] =>)